You just read:

Gilead receives approval in Canada for EPCLUSA™ (sofosbuvir/velpatasvir), the first once-daily pan-genotypic (genotypes 1-6) single tablet regimen for the treatment of chronic hepatitis C

News provided by

Gilead Sciences, Inc.

Jul 14, 2016, 07:30 ET